MRS2179 (ammonium salt hydrate)

Confirm delete?

Zoom

Cat No: 10011450

Biochemicals - Receptor Pharmacology

MRS2179 is a competitive purinergic P2Y1 receptor antagonist (Kb = 102 nM).{53657} It is selective for P2Y1 over P2Y2, P2Y4, P2Y6, P2Y12, and P2Y13, as well as P2X1-4, receptors at 10 µM.{19258,53658} MRS2179 reduces phospholipase C (PLC) activity ind...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2?-deoxy-N-methyl-3?-adenylic acid, 5?-(dihydrogen phosphate), ammonium salt, hydrate

Correlated keywords:

platelet aggregation P2Y1 P2Y-1 MRS-2179 2'-deoxy-N6-methyladenosine 3',5'-bisphosphate 101204-49-3 228264-19-5

Product Overview:
MRS2179 is a competitive purinergic P2Y1 receptor antagonist (Kb = 102 nM).{53657} It is selective for P2Y1 over P2Y2, P2Y4, P2Y6, P2Y12, and P2Y13, as well as P2X1-4, receptors at 10 µM.{19258,53658} MRS2179 reduces phospholipase C (PLC) activity induced by the P2Y receptor agonist 2-methylthioadenosine diphosphate (2-MeSADP; Item No. 21230) with an IC50 value of 331 nM in turkey erythrocyte membranes that endogenously express high levels of the P2Y1 receptor.{53657} It inhibits platelet shape change and aggregation induced by ADP (Item No. 21121) in washed isolated human platelets when used at a concentration of 10 µM.{33272} MRS2179 (50 mg/kg, i.v.) prolongs the length of tail bleeding time in mice, as well as decreases platelet thrombus formation in a mouse model of iron chloride-induced arterial thrombosis.{33272,53659}

Size	1 mg
Shipping	dry ice
Molecular Formula	C₁₁H₁₇N₅O₉P₂ • XNH₃ [XH₂O]
SMILES	OP(OC[C@@H]1[C@@H](OP(O)(O)=O)C[C@H](N2C=NC3=C2N=CN=C3NC)O1)(O)=O.N.O
Molecular Weight	425,2
Formulation	A solid
Purity	≥98%
Custom Code	2932.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.